On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating ... on rips ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.22 which represents a slight increase of $0.38 or 0.42% from the prior close of $89.84. The stock opened at ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

Shares of Gilead Sciences Inc. GILD slipped 1.36% to $96.57 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.38% to 5,995. ...

Shares of Gilead Sciences Inc. GILD rallied 1.63% to $91.69 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 2.53% to ...

This page features the latest news about the Gilead Sciences DRC stock. FDA grants accelerated approval to Gilead's Livdelzi for PBC FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) has ...

But can this momentum be sustained? Gilead Sciences, Inc., is a leading biopharmaceutical company headquartered in Foster City, California. Founded in 1987, it has established itself as a global ...

In a report released yesterday, Tyler Van Buren from TD Cowen maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a ...